Emily Ruiz, MD, MPH, FAAD

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Experts in dermatology discuss treatment considerations for particular patient populations, highlighting the importance of managing adverse events aggressively.

Experts in dermatology discuss the efficacy and safety combining hedgehog pathway inhibitors and immunotherapy as treatment for patients with basal cell carcinoma.

Todd Schlesinger, MD and Emily Ruiz, MD offer advice on forming multidisciplinary relationships for the wholistic study and treatment of basal cell carcinoma.

Emily Ruiz, MD and Todd Schlesinger, MD discuss treatment options for locally advanced basal cell carcinoma, such as immunotherapy and surgery.